Thus, sitagliptin is worthy of close attention not only as an anti-diabetic medication but also as a potent treatment for diabetic cardiomyopathy that targets the Nrf2/Keap1 signaling pathway. Here, NFE2L2 is linked to diabetic cardiomyopathy.